Stocks making the biggest moves midday: Dick's Sporting Goods, Marvell, AMD, Kura Oncology & more

Dick's Sporting Goods shares fell over 27% after revenue missed estimates ($5.59B vs $5.65B expected), citing a challenging footwear market. Offsetting gains were mixed across tech and healthcare: Dynatrace rose ~3% on a Morgan Stanley overweight upgrade, Moderna rallied ~13% after Wolfe upgraded and cited positive joint cancer vaccine trial momentum, while Marvell and AMD each gained ~5% on price-target/ratings raises. Shift4 Payments added nearly 4% following a Wells Fargo upgrade, and Navitas Semiconductor jumped ~5% on a $232.8M cash-and-stock deal to power Claros, supporting a net neutral-to-uncertain tape with pockets of stock-specific upside.

Analysis

The cleanest read-through is not “consumer is breaking,” but that category mix is getting more promotional where unit growth is easiest to fake and hardest to defend. For retailers with footwear exposure, the first-order hit is margin, but the second-order risk is a reset in buy plans that shows up over the next 1-2 inventory cycles; that is more important than the one-day stock move. I would treat this as an alert on discretionary demand rather than a broad macro short until peer commentary from other retailers confirms the same deterioration.

In semis, the better trade is relative performance, not directional beta. The market is rewarding evidence that custom silicon and CPU share gains can support both revenue and margin; that is structurally negative for legacy CPU incumbents and positive for names with design-win momentum. The near-term hazard is event risk into earnings: if order visibility or hyperscaler commentary disappoints, the multiple can compress quickly even if the secular story is intact.

The software and biotech moves are mostly quality-of-narrative rather than quality-of-cash-flow. DT and FOUR can compound if the sell-side is right on margin expansion, but after modest upgrades the upside is usually time-dependent, not immediate; the better entry is on post-earnings or market-wide weakness. MRNA and KURA are more flow-driven: momentum can persist for days to weeks, but the thesis is vulnerable if the next clinical or regulatory checkpoint fails to validate the current enthusiasm.

Contrarian view: the market may be overpricing the durability of the current biotech and AI-related enthusiasm while underpricing how quickly retail promotions can spread to adjacent categories. The strongest actionable expression is still the AMD/INTC spread; everything else looks more tactical than structural at current levels.

Key Decisions for Investors

• Long AMD / short INTC for 1-3 months as a relative-value share-gain trade; target a 10-15% spread if AMD keeps taking CPU mix and INTC cannot show stable share trends. Falsifier: any INTC guidance improvement or AMD commentary that does not support further server/CPU share gains.
• Do not chase MRVL into Thursday earnings; if you want exposure, wait for the print and buy only on a guide-confirmed pullback. The setup is attractive only if custom XPU/Google commentary is reiterated; otherwise the stock can de-rate fast on any visibility miss.
• Treat DKS as a consumer-discretionary warning shot, but wait for a reflex rally to short rather than fading the gap immediately. Target 1-2 months for additional estimate cuts; exit if management stabilizes gross margin or if peer retail reads do not confirm footwear weakness.
• Buy DT or FOUR only on market weakness, not after the upgrade pop. These are 6-12 month compounders if margin expansion persists, but the near-term risk/reward is poor after modest re-ratings.
• Avoid chasing MRNA at current momentum levels; if trading it, use a small defined-risk call spread only if the next oncology update extends the narrative. Falsifier: any delay, dilution, or lack of follow-through in specialist buying.